Santarus Inc (SNTS.OQ)

SNTS.OQ on NASDAQ Stock Exchange Global Select Market

24.59USD
10:56am EDT
Price Change (% chg)

$0.27 (+1.11%)
Prev Close
$24.32
Open
$24.58
Day's High
$24.85
Day's Low
$24.39
Volume
111,074
Avg. Vol
380,864
52-wk High
$25.99
52-wk Low
$4.90

SNTS.OQ

Chart for SNTS.OQ

About

Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company’s marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium... (more)

Overall

Beta: 1.31
Market Cap (Mil.): $1,587.31
Shares Outstanding (Mil.): 65.27
Dividend: --
Yield (%): --

Financials

  SNTS.OQ Industry Sector
P/E (TTM): 48.54 37.93 37.76
EPS (TTM): 0.50 -- --
ROI: 37.82 19.48 18.76
ROE: 44.68 20.17 19.59
Search Stocks

Santarus raises full-year forecast as diabetes drug sales jump

- Pharmaceutical company Santarus Inc raised its full-year outlook for the second time this year driven by strong first-quarter sales, especially of its diabetes drug Glumetza, sending its shares up 11 percent after the bell.

06 May 2013

Competitors

  Price Change
Pfizer Inc. (PFE.N) $29.18 -0.05
Novartis AG (NOVN.VX) CHF66.60 +0.35
Roche Holding Ltd. (ROG.VX) CHF228.00 -3.50
Abbott Laboratories (ABT.N) $36.92 +0.29
Sanofi SA (SASY.PA) €76.26 -3.91
Eli Lilly & Co. (LLY.N) $53.23 +0.12

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks